Topical tacrolimus for atopic dermatitis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Cury Martins, Jade ^a   Martins, Ciro ^b   Aoki, Valeria ^c   Gois, Aecio F T ^a   Ishii, Henrique A ^d   da Silva, Edina M K ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Belecara Premium Multispecialty Center   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORINE; PIMECROLIMUS; STEROID; TACROLIMUS; CALCINEURIN INHIBITOR; DERMATOLOGICAL AGENT;

ATOPIC DERMATITIS; BURN; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN INFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DERMATITIS, ATOPIC; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; CALCINEURIN INHIBITORS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS;

EID: 84957415069     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009864.pub2     Document Type: Review

References (169)

1. Antiga E, Volpi W, Torchia D, Fabbri P, Caproni M. Effects of tacrolimus ointment on Toll-like receptors in atopic dermatitis. Clinical & Experimental Dermatology 2011;36(3):235-41. [MEDLINE: 21070333]
2. Bieber T, Vick K, Folster-Holst R, Belloni-Fortina A, Stadtler G, Worm M, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007;62(2):184-9. [MEDLINE: 17298428]
3. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy & Clinical Immunology 1998;102(4 Pt 1):637-44. [MEDLINE: 9802373]
4. Caproni M, Torchia D, Antiga E, Terranova M, Volpi W, del Bianco E, et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology 2007;156(2):312-9. [MEDLINE: 17223872]
5. Doss N, Kamoun MR, Dubertret L, Cambazard F, Remitz A, Lahfa M, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy & Immunology 2010;21(2 Pt 1):321-9. [MEDLINE: 19563466]
6. Dou X, Liu L-L, Xie Z-Q, Chen L-J, Li L, Feng S-Y, et al. The impact of tacrolimus ointment on health-related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology 2006;35(1):50-2.
7. Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. Journal of the American Academy of Dermatology 2005;53(4):602-9. [MEDLINE: 16198779]
8. Fleischer AB Jr, Abramovits W, Breneman D, Jaracz E, US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment 2007;18(3):151-7. [MEDLINE: 17538803]
9. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology 2001;44(Suppl 1):S28-38. [EMBASE: 2001020450]
10. Soter NA, Fleischer Jr. AB, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology 2001;44(1 Suppl):S39-46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451]
11. Hung SH, Lin YT, Chu CY, Lee CC, Liang TC, Yang YH, et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, & Immunology 2007;98(1):51-6. [MEDLINE: 17225720]
12. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology 2004;51(4):515-25. [MEDLINE: 15389185]
13. Otsuki, M, Kawashima, M, Shibata, Y, Nakagawa, H, Harada, S. Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis-Phase III Double-blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics & Medicines (Rinsho Iyaku) 2003;19:569-95.
14. Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Rini GB, Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical & Experimental Allergy 2004;34(4):639-45. [MEDLINE: 15080819]
15. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology 2001;44(1 Suppl):S47-57. [MEDLINE: 11145795]
16. Abramovits W, Fleischer AB Jr, Jaracz E, Breneman D. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology 2008;7(12):1153-8. [MEDLINE: 19137769]
17. Paller AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology 2005;52(5):810-22. [MEDLINE: 15858471]
18. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy & Clinical Immunology 2002;109(3):547-55. [MEDLINE: 11898005]
19. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy & Clinical Immunology 2002;109(3):539-46. [MEDLINE: 11898004]
20. Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. British Journal of Dermatology 2004;150(3):554-62. [MEDLINE: 15030341]
21. Mandelin J, Remitz A, Virtanen H, Reitamo S. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial. Acta Dermato-Venereologica 2010;90(2):170-4. [DOI: 10.2340/00015555-0803; MEDLINE: 20169301]
22. Poole CD, Chambers C, Allsopp R, Currie CJ. Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology & Venereology 2010;24(6):674-8. [DOI: 10.1111/j.1468-3083.2009.03485.x; MEDLINE: 20565562]
23. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology 2005;152(6):1282-9. [MEDLINE: 15948994]
24. Sikder Md AU, Al Mamun S, Khan RM, Chowdhury AH, Khan HM, Hoque MM. Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis - An open randomized comparative study. Journal of Pakistan Association of Dermatologists 2005;15(4):304-12. [EMBASE: 2006159825]
25. Arkwright PD, Gillespie MC, Ewing CI, David TJ. Blinded side-to-side comparison of topical corticosteroid and tacrolimus ointment in children with moderate to severe atopic dermatitis. Clinical & Experimental Dermatology 2007;32(2):145-7. [MEDLINE: 17342794]
26. Chapman MS, Schachner LA, Breneman D, Boguniewicz M, Gold MH, Shull T, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology 2005;53(2 Suppl 2):177-85. [MEDLINE: 16021173]
27. Dähnhardt-Pfeiffer S, Dähnhardt D, Buchner M, Walter K, Proksch E, Fölster-Holst R. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. Journal Der Deutschen Dermatologischen Gesellschaft 2013;11(5):437-43. [MEDLINE: 23551950]
28. Del Rosso JQ, Conte ET. An Investigator-Blinded Evaluation of Fluocinonide 0.1% Cream in the Treatment of Atopic Dermatitis and Psoriasis Vulgaris. Cosmetic Dermatology 2007;20(9):545-52. [EMBASE: 2007500429]
29. Doss N, Reitamo S, Dubertret L, Fekete GL, Kamoun MR, Lahfa M, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. British Journal of Dermatology 2009;161(2):427-34. [MEDLINE: 19416227]
30. Gradman J, Wolthers OD. Short-term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. Acta Paediatrica 2007;96(8):1233-7. [MEDLINE: 17590198]
31. Granlund H, Remitz A, Kyllonen H, Lauerma AI, Reitamo S. Treatment of Lichenified Atopic Eczema with Tacrolimus Ointment. Acta Dermato-Venereologica 2001;81(4):314-5. [MEDLINE: 11720192]
32. Hebert AA, Koo J, Fowler J, Berman B, Rosenberg C, Levitt J. Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. Cutis 2006;78(5):357-63. [MEDLINE: 17186796]
33. Hjelmgren J, Svensson A, Jorgensen ET, Lindemalm-Lundstam B, Ragnarson Tennvall G. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. British Journal of Dermatology 2007;156(5):913-21. [MEDLINE: 17263826]
34. Ishibashi Y, Nakagawa H, Eto T, Kawashima M, Higaki Y, Harada S, et al. Early Phase II Study of FK506 Ointment on Atopic Dermatitis. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines) 1997;13(2):317-39.
35. Kang S, Paller A, Soter N, Satoi Y, Rico MJ, Hanifin JM. Safe treatment of head/neck AD with tacrolimus ointment. Journal of Dermatological Treatment 2003;14(2):86-94. [MEDLINE: 12775315]
36. Kirsner RS, Heffernan MP, Antaya R. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Dermato-Venereologica 2010;90(1):58-64. [MEDLINE: 20107727]
37. Liu LL, Dou X, Xie ZQ, Wand D, Zheng ZZ, Wei MH, et al. Efficacy and Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Chinese Children. Chinese Journal of Dermatology 2005;38(10):608-11.
38. Neumann E, Amtage D, Bruckner-Tuderman L, Mockenhaupt M. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. Journal Der Deutschen Dermatologischen Gesellschaft 2008;6(7):548-53. [MEDLINE: 18248495]
39. Onumah N, Kircik L. Pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis: A pilot study on patient preference. Journal of Drugs in Dermatology 2013;12(10):1145-8. [MEDLINE: 24085050]
40. Rahman MF, Rashid MM, Sikder AU, Akhtar N, Banu LA, Wahab MA. Efficacy of topical tacrolimus in atopic dermatitis. Journal of Pakistan Association of Dermatologists 2008;18(2):84-92. [EMBASE: 2008404671]
41. Reitamo S, Mandelin J, Rubins A, Remitz A, Makela M, Cirule K, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. International Journal of Dermatology 2009;48(4):348-55. [MEDLINE: 19335418]
42. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. New England Journal of Medicine 1997;337(12):816-21. [MEDLINE: 9295241]
43. Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics 2005;116(3):e334-42. [MEDLINE: 16140675]
44. Takeuchi S, Saeki H, Tokunaga S, Sugaya M, Ohmatsu H, Tsunemi Y, et al. A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis. Annals of Dermatology 2012;24(2):144-50. [MEDLINE: 22577263]
45. Torok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis 2003;72(2):161-6. [MEDLINE: 12953943]
46. Won CH, Seo PG, Park YM, Yang JM, Lee KH, Sung KJ, et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. Journal of Dermatological Treatment 2004;15(1):30-4. [MEDLINE: 14754647]
47. Xhauflaire-Uhoda E, Thirion L, Piérard-Franchimont C, Piérard GE. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatology 2007;214(4):328-32. [MEDLINE: 17460405]
48. Drake L, Prendergast M, Maher R, Breneman D, Korman N, Satoi Y, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. Journal of the American Academy of Dermatology 2001;44(1 Suppl):S65-72. [MEDLINE: 11145797]
49. NCT00475605. APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT00475605 (accessed 8 October 2014).
50. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61(8):969-987. [MEDLINE: 16867052]
51. Aldea A, Garcia Sanchez-Colomer M, Fernandez Quintana E, Garcia Saiz M. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. European Journal of Clinical Pharmacology 2012;68(9):1329-38. [MEDLINE: 22415248]
52. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Archives of Dermatology 2001;137(6):747-50. [MEDLINE: 11405764]
53. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Archives of Dermatology 2002;138(9):1259-60. [MEDLINE: 12225004]
54. Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Archives of Dermatology 2004;140(4):457-60. [MEDLINE: 15096374]
55. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Journal of Investigative Dermatology 2007;127(4):808-16. [MEDLINE: 17096020]
56. Arellano FM, Arana A, Wentworth CE, Fernandez-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Journal of Allergy & Clinical Immunology 2009;123(5):1111-6. [MEDLINE: 19361841]
57. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005;330(7490):516. [MEDLINE: 15731121]
58. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005;330(7490):516. [MEDLINE: 15731121]
59. Ashcroft DM, Chen L, Garside R, Stein K, Williams HC. Topical pimecrolimus for eczema. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005500.pub2]
60. Asher MI, Stewart AW, Mallol J, Montefort S, Lai CK, Aït-Khaled N, et al. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. Respiratory Research 2010;11:8. [MEDLINE: 20092649]
61. Bath-Hextall FJ, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD005203.pub2]
62. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. Journal of the American Academy of Dermatology 2001;44(1 Suppl):S17-27. [MEDLINE: 11145792]
63. Bens G, Boralevi F, Buzenet C, Taïeb A. Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. British Journal of Dermatology 2003;149(1):224-226. [MEDLINE: 12890237]
64. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ, American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. Journal of the American Academy of Dermatology 2006;54(5):818-23. [MEDLINE: 16635663]
65. Beyeler M, Schmid-Grendelmeier P, Hafner J. Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. Dermatology 2006;212(3):260-261. [MEDLINE: 16549924]
66. Boguniewicz M, Leung DY. Atopic Dermatitis. Journal of Allergy & Clinical Immunology 2006;117(2 Suppl Mini-Primer):S475-S480. [MEDLINE: 16455350]
67. Bos JD, Brenninkmeijer EE, Schram ME, Middelkamp-Hup MA, Spuls PI, Smitt JH. Atopic eczema or atopiform dermatitis. Experimental Dermatology 2010;19(4):325-31. [MEDLINE: 20100192]
68. Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatric Dermatology 2009 Jan-Feb;26(1):14-22. [MEDLINE: 19250399]
69. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology 2005;6(2):65-77. [MEDLINE: 15799678]
70. Böhme M, Svensson A, Kull I, Nordvall SL, Wahlgren CF. Clinical features of atopic dermatitis at two years of age: a prospective, population-based case-control study. Acta Dermato-Venereologica 2001;81(3):193-7. [MEDLINE: 11558876]
71. Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, et al. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology 2007;156(2):203-21. [MEDLINE: 17223859]
72. Calza AM, Lubbe J. Tacrolimus ointment-associated alcohol intolerance in infants receiving ethanol-containing medication. British Journal of Dermatology 2005;152(3):569. [MEDLINE: 15787832]
73. Castelo-Soccio L, Di Marcantonio D, Shah P, Lee LW, Treat JR, Yan AC. Induced lentiginosis with use of topical calcineurin inhibitors. Archives of Dermatology 2012;148(6):766-8. [MEDLINE: 22710469]
74. Chamlin SL, Frieden IJ, Williams ML, Chren MM. Effects of atopic dermatitis on young American children and their families. Pediatrics 2004;114(3):607-11. [MEDLINE: 15342828]
75. Charman C, Williams H. Outcome Measures of Disease Severity in Atopic Eczema. Archives of Dermatology 2000;136(6):763-9. [DOI: 10.1001/archderm.136.6.763; MEDLINE: 10871941]
76. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. Journal of Dermatological Treatment 2010;21(3):144-56. [MEDLINE: 20394490]
77. Cho M, Puma I, Nguyen D, Schut R, Glesne L. Development of Kaposi's sarcoma in an AIDS patient after treatment with topical tacrolimus. Journal of the American Academy of Dermatology 2004;50(1):149-50. [MEDLINE: 14699390]
78. Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues. Journal Der Deutschen Dermatologischen Gesellschaft 2012;10(3):167-72. [MEDLINE: 21974750]
79. Ehst BD, Warshaw EM. Alcohol-induced application site erythema after topical immunomodulator use and its inhibition by aspirin. Archives of Dermatology 2004;140(8):1014-5. [MEDLINE: 15313828]
80. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology 2014;70(2):338-51. [MEDLINE: 24290431]
81. El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. Journal of Dermatological Science 2009;54(2):76-87. [MEDLINE: 19303745]
82. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [MEDLINE: 11914310]
83. Ellis CN, Mancini AJ, Paller AS, Simpson EL, Eichenfield LF. Understanding and managing atopic dermatitis in adult patients. Seminars in Cutaneous Medicine & Surgery 2012;31(3 Suppl):S18-22. [MEDLINE: 23021781]
84. Ellwood P, Asher MI, Björkstén B, Burr M, Pearce N, Robertson CF. Diet and asthma, allergic rhinoconjunctivitis and atopic eczema symptom prevalence: an ecological analysis of the International Study of Asthma and Allergies in Childhood (ISAAC) data. ISAAC Phase One Study Group. European Respiratory Journal 2001 Mar;17(3):436-43. [MEDLINE: 11405522]
85. Finch J, Munhutu MN, Whitaker-Worth DL. Atopic dermatitis and nutrition. Clinics in Dermatology 2010;28(6):605-14. [MEDLINE: 21034985]
86. WolffK, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Fitzpatrick's Dermatology in General Medicine. 7th Edition. Vol. 1, United States: The McGraw-Hill Companies, 2008.
87. FK506 Ointment Study Group. Long-term study of FK506 (tacrolimus) ointment in patients with atopic dermatitis - analysis at time of completion of 2-year observation. Journal of Clinical Therapeutics and Medicines 2001;17(5):705-726.
88. Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel-Broadbent J, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. Journal of Allergy & Clinical Immunology 2005;115(6):1249-53. [MEDLINE: 15940142]
89. Fujiwara S, Okubo Y, Irisawa R, Tsuboi R. Rosaceiform dermatitis associated with topical tacrolimus treatment. Journal of the American Academy of Dermatology 2010;62(6):1050-2. [MEDLINE: 20466178]
90. Goldman D. Tacrolimus ointment for thetreatment of steroid-induced rosacea: a preliminary report. Journal of the American Academy of Dermatology 2001;44(6):995-8. [MEDLINE: 11369912]
91. Gontijo B, Pires MC, Cestari TF, La Scala CSK, Duarte IAG, Takaoka R, et al. Evaluate of the efficacy and safety of tacrolimus ointment 0, 03% to treat atopic dermatitis in pediatric patients [Avaliacao da eficacia e seguranca do tacrolimo pomada 0, 03% no tratamento da dermatite atopica em pacientes pediatricos]. Anais Brasileiros De Dermatologia 2008;83(6):511-9. [MEDLINE: 2009148842]
92. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [EMBASE: 2008218668]
93. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato-Vereneologica 1980;92(Suppl):44-7.
94. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Experimental Dermatology 2001;10(1):11-8. [MEDLINE: 11168575]
95. Harper J, Smith C, Rubins A, Green A, Jackson K, Zigure S, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. Journal of Investigative Dermatology 2005;124(4):695-9. [MEDLINE: 15816825]
96. Harrop J, Chinn S, Verlato G, Olivieri M, Norbäck D, Wjst M, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clinical & Experimental Allergy 2007;37(4):526-35. [MEDLINE: 17430349]
97. Hickey JR, Robson A, Barker JN, Smith CH. Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. British Journal of Dermatology 2005;152(1):152-4. [MEDLINE: 15656817]
98. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
99. Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Annals of Pharmacotherapy 2009;43(12):1956-63. [MEDLINE: 19903860]
100. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211(2):174-87. [MEDLINE: 16088174]
101. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of theSF-36 version 2 in the United Kingdom. Journal of Epidemiology & Community Health 1999;53(1):46-50. [MEDLINE: 10326053]
102. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy & Clinical Immunology 2004;113(5):832-6. [MEDLINE: 15131563]
103. Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. British Journal of Cancer 2001;85(5):683-6. [MEDLINE: 11531252]
104. Knight AK, Boxer M, Chandler MJ. Alcohol-induced rash caused by topical tacrolimus. Annals of Allergy, Asthma, & Immunology 2005;95(3):291-2. [MEDLINE: 16200821]
105. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Modern Pathology 1999;12(2):200-17. [MEDLINE: 10071343]
106. Koo JY, Fleischer AB Jr, Abramovits W, Pariser DM, McCall CO, Horn TD, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. Journal of the American Academy of Dermatology 2005;53(2 Suppl 2):S195-205. [MEDLINE: 16021175]
107. Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. British Journal of Dermatology 2004;150(6):1174-1181. [MEDLINE: 15214906]
108. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Archives of Dermatology 2003;139(5):581-585. [MEDLINE: 12756094]
109. Lin Y, Sun IW, Liu SI, Loh el-W, Lin YC. Tacrolimus ointment-induced relapse of schizophrenia: a case report. International Journal of Neuropsychopharmacology 2007;10(6):851-4. [MEDLINE: 18077846]
110. Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, De Giorgi V, et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatologic Therapy 2008;21(Suppl 1):S20-6. [MEDLINE: 18727812]
111. Luger TA, Gollnick H. Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis) [Stellungnahme Der Deutschen Dermatologischen Gesellschaft (DDG) Zur Entscheidung Der Amerikanischen Arzneimittelbehorde (FDA) Uber Die Verwendung Von Pimecrolimus-Creme Und Tacrolimus-Salbe Zur Behandlung Der Atopischen Dermatitis (Neurodermitis)]. Journal Der Deutschen Dermatologischen Gesellschaft 2005;3(6):415-6. [MEDLINE: 15892843]
112. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. Journal of the European Academy of Dermatology & Venereology 2011;25(3):251-8. [MEDLINE: 21294777]
113. Macias ES, Pereira FA, Rietkerk W, Safai B. Superantigens in dermatology. Journal of the American Academy of Dermatology 2011;64(3):455-72. [MEDLINE: 21315950]
114. Maddin S. Pimecrolimus and tacrolimus: the US FDA public health advisory. Skin Therapy Letter 2005;10(4):1-3. [MEDLINE: 15986080]
115. Maksimović N, Janković S, Marinković J, Sekulović LK, Zivković Z, Spirić VT. Health-related quality of life in patients with atopic dermatitis. Journal of Dermatology 2012;39(1):42-7. [MEDLINE: 22044078]
116. Mandelin JM, Rubins A, Remitz A, Cirule K, Dickinson J, Ho V, et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study. International Journal of Dermatology 2012;51(1):104-10. [MEDLINE: 21923693]
117. Margolis DJ, Hoffstad O, Bilker, W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214(4):289-95. [MEDLINE: 17460399]
118. McCollum AD, Paik A, Eichenfield LF. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatric Dermatology 2010;27(5):425-36. [MEDLINE: 20678096]
119. Medline Plus®. Medical Dictionary. http://www.merriam-webster.com/medlineplus/antibody (accessed 30 July 2013).
120. Medline Plus®. Medical Dictionary. http://www.merriam-webster.com/medlineplus/prick%20test (accessed 30 July 2013).
121. Milingou M, Antille C, Sorg O, Saurat JH, Lubbe J. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Archives of Dermatology 2004;140(12):1542-4. [MEDLINE: 15611445]
122. Mitamura T, Doi Y, Kawabe M, Lilja H, Motomura M, Oishi Y, et al. Inhibitory potency of tacrolimus ointment on skin tumor induction in a mouse model of an initiation-promotion skin tumor. Journal of Dermatology 2011;38(6):562-70. [MEDLINE: 21352294]
123. Momtaz K, Fitzpatrick TB. The benefits and risks of long-term PUVAphotochemotherapy. Dermatologic Clinics 1998;16(2):227-34. [MEDLINE: 9589196]
124. Naylor M, Elmets C, Jaracz E, Rico JM. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Journal of Dermatological Treatment 2005;16(3):149-53. [MEDLINE: 16096180]
125. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy & Clinical Immunology 2009;124(6):1251-8. [MEDLINE: 20004783]
126. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. British Journal of Dermatology 2005;153(4):701-5. [MEDLINE: 16181449]
127. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Archives of Dermatology 2003;139(9):1184-6. [MEDLINE: 12975161]
128. Patel TS, Greer SC, Skinner RB Jr. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. American Journal of Clinical Dermatology 2007;8(4):189-94. [MEDLINE: 17645374]
129. Pitarch G, Torrijos A, Mahiques L, Sánchez-Carazo JL, Fortea JM. Systemic absorption of topical tacrolimus in Pyoderma gangrenosum. Acta Dermato-Venereologica 2006;86(1):64-65. [MEDLINE: 16585995]
130. Rajka G, Langeland T. Grading of the severity of atopic dermatits. Acta Dermato-Venereologica. Supplementum 1989;144:13-4. [MEDLINE: 2800895]
131. Rehal B, Armstrong AW. Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985-2010. PLoS ONE 2011;6(4):e17520. [DOI: 10.1371/journal.pone.0017520; MEDLINE: 21533286]
132. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. Journal of Investigative Dermatology 1998;111(3):396-8. [MEDLINE: 9740230]
133. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus OintmentStudy Group. Archives of Dermatology 2000;136(8):999-1006. [MEDLINE: 10926735]
134. Reitamo S, Rubins A, Ho V, et al. Pharmacokinetics of topical tacrolimus in paediatric patients aged 3 to 24 months. 15th Congress of the European Academy of Dermatology andVenereology, Rhodes, Greece. 2006.
135. Reitamo S, Ortonne JP, Sand C, Bos J, Cambazard F, Bieber T, et al. Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, non-comparative study. Acta Dermato-Venereologica 2007;87(5):406-12. [EMBASE: 17721647]
136. Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. British Journal of Dermatology 2008;159(4):942-51. [MEDLINE: 18637898]
137. Remitz A, Harper J, Rustin M, Goldschmidt WF, Palatsi R, van der Valk PG, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Dermato-Venereologica 2007;87(1):54-61. [MEDLINE: 17225017]
138. Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. Journal of the European Academy of Dermatology & Venereology 2005;19(6):663-71. [MEDLINE: 16268869]
139. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review. Journal of Allergy & Clinical Immunology 2014;133(2):429-438. [MEDLINE: 24269258]
140. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. British Journal of Dermatology 2007;157(5):861-73. [MEDLINE: 17854353]
141. Saif GB, Al-Khenaizan S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. International Journal of Dermatology 2007;46(3):290-294. [MEDLINE: 17343588]
142. Saple DG, Torsekar RG, Pawanarkar V, Wali V, Ravichandran G, Dhanalakshmi UR, et al. Evaluation of the efficacy, safety and tolerability of Tacrolimus ointment in Indian patients of moderate to severe atopic dermatitis: a multicentric, open label, phase III study. Indian Journal of Dermatology, Venereology & Leprology 2003;69(6):396-400. [MEDLINE: 17642950]
143. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. British Journal of Dermatology 2011;164(2):415-28. [MEDLINE: 20819086]
144. Schmutz JL, Barbaud A, Trechot P. Kaposi's sarcoma in an AIDS patient after application of tacrolimus (Protopic) [Maladie de Kaposi chez un sujet sideen apres application de tacrolimus (Protopic)]. Annales de Dermatologie et de Venereologie 2006;133(3):303. [MEDLINE: 16800194]
145. Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009;219(1):7-21. [MEDLINE: 19293564]
146. Schwarz T, Kreiselmaier I, Bieber T, Thaci D, Simon JC, Meurer M, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. Journal of the American Academy of Dermatology 2008;59(1):34-40. [MEDLINE: 18462835]
147. Segal AO, Ellis AK, Kim HL. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy, Asthma, & Clinical Immunology: Official Journal of the Canadian Society of Allergy & Clinical Immunology 2013;9(1):24. [MEDLINE: 23837743]
148. Shaw DW, Eichenfield LF, Shainhouse T, Maibach HI. Allergic contact dermatitis from tacrolimus. Journal of the American Academy of Dermatology 2004;50(6):962-5. [MEDLINE: 15153904]
149. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. American Journal of Clinical Dermatology 2013;14(3):163-78. [MEDLINE: 23703374]
150. Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy 2014;69(1):46-55. [MEDLINE: 24354911]
151. Skowron F, Dalle S, Marcilly MC, Balme B, Thomas L. Important systemic absorption of topical tacrolimus during treatment of severe pemphigus vulgaris. Annales de Dermatologie et de Venereologie 2005;132(3):263-5. [MEDLINE: 15924053]
152. Soderberg KC, Hagmar L, Schwartzbaums J, Feychting M. Allergic conditions and the risk of hematological malignancies in adults: a cohort study. BMC Public Health 2004;4:51. [MEDLINE: 15527506]
153. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. Journal of the National Cancer Institute 2004;96(9):709-11. [MEDLINE: 15126608]
154. Stern RS, PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. Journal of the American Academy of Dermatology 2001;44(5):755-61. [MEDLINE: 11312420]
155. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination in children with atopic dermatitis treated with tacrolimus ointment. Journal of the American Academy of Dermatology 2005;53(2 Suppl 2):S206-13. [MEDLINE: 16021176]
156. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299(6710):1259-60. [MEDLINE: 2513902]
157. Svensson A, Chambers C, Ganemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Current Medical Research & Opinion 2011;27(7):1395-406. [MEDLINE: 21563877]
158. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. British Journal of Dermatology 2011;165(3):465-73. [MEDLINE: 21466537]
159. Teraki Y, Hitomi K, Sato Y, Izaki S. Tacrolimus-induced rosacea-like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology 2012;224(4):309-14. [MEDLINE: 22626964]
160. Tran C, Lubbe J, Sorg O, Doelker L, Carraux P, Antille C, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005;211(4):341-7. [MEDLINE: 16286744]
161. US Food, Drug Administration (FDA). Pediatric Advisory Committee February 15th 2005. Briefing Information. Labeling Information and NDAs. www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm (accessed 5 December 2013).
162. Weischer M, Rocken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion?. Experimental Dermatology 2007;16(5):385-93. [MEDLINE: 17437481]
163. Williams H, Robertson C, Stewart A, Aït-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. Journal of Allergy & Clinical Immunology 1999;103(1 Pt 1):125-38. [MEDLINE: 9893196]
164. Wong WR, Tsai HJ, Hong HS. Efficacy and safety of topically applied tacrolimus ointment in patients with moderate to severe atopic dermatitis. Chang Gung Medical Journal 2003;26(7):485-95. [MEDLINE: 14515971]
165. Yan J, Chen SL, Wang XL, Zhou W, Wang FS. Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatric Dermatology 2008;25(1):117-20. [MEDLINE: 18304172]
166. Yin ZQ, Zhang WM, Song GX, Luo D. Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis. Journal of Dermatology 2012;39(6):520-6. [MEDLINE: 22409418]
167. Zattra E, Albertin C, Belloni Fortina A. Labial melanotic macule after application of topical tacrolimus: two case reports. Acta Dermato-Venereologica 2010;90(5):527. [MEDLINE: 20814635]
168. Zonneveld IM, De Rie MA, Beljaards RC, Van Der Rhee HJ, Wuite J, Zeegelaar J, et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. British Journal of Dermatology 1996;135(Suppl 48):15-20. [MEDLINE: 8881899]
169. Cury Martins J, Martins C, Aoki V, Leonardi-Bee J, Gois AFT, Ishii HA, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009864]